Opens in a new tab

Dr. Wu Yilong

Chinese name: 吴一龙
Chief Expert, Professor, Chief Physician, Doctoral Supervisor, FACS . Thoracic Oncology
Dr. Wu Yilong is Chief Expert at Guangdong Provincial People's Hospital and Honorary Director of the Guangdong Lung Cancer Institute. A Fellow of the American College of Surgeons and chairman of the Chinese Thoracic Oncology Group, he has led practice-changing lung cancer trials that reshaped international treatment guidelines.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

40+
Years in Thoracic Oncology Practice
7
Papers Published in the New England Journal of Medicine
6
Years Ranked as a Clarivate Highly Cited Researcher

  • The Physician

About Dr. Wu Yilong

Dr. Wu Yilong is Chief Expert at Guangdong Provincial People's Hospital, Honorary Director of the Guangdong Lung Cancer Institute and a Fellow of the American College of Surgeons. As founder and chairman of the Chinese Thoracic Oncology Group, he has designed and led numerous international multicentre trials in EGFR-mutant and resected non-small-cell lung cancer, including the ADJUVANT and ADAURA studies, which established targeted therapy as a global standard of care. His research on precision oncology and drug-resistance mechanisms has been published in leading journals, and he has been listed among the world's most highly cited researchers for six consecutive years.
1、Chief Expert of Guangdong Provincial People’s Hospital and Honorary Director of the Guangdong Lung Cancer Institute
2、Fellow of the American College of Surgeons (FACS)
3、Founder and Chairman of the Chinese Thoracic Oncology Group (CTONG)
4、Principal investigator of the ADJUVANT and ADAURA trials that changed global lung cancer guidelines
5、Listed among the world’s most highly cited researchers for six consecutive years
6、Recipient of the State Council Special Allowance

Dr. Wu Yilong ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Lung cancer precision therapy

As one of China's leading thoracic oncologists, he matches patients with targeted and immune therapies based on tumour molecular profiling, designing individualized treatment plans that improve survival, quality of life and tolerability for advanced non-small-cell lung cancer and other thoracic malignancies.

EGFR-mutant lung cancer

He is internationally recognized for establishing adjuvant targeted therapy for resected EGFR-mutant lung cancer, leading randomised trials such as ADJUVANT and ADAURA that significantly extended disease-free and overall survival and redefined postoperative standards of care and treatment sequencing for patients worldwide.

Multidisciplinary lung cancer care

He leads comprehensive multidisciplinary teams that integrate surgery, radiotherapy, pathology and molecular diagnostics, ensuring patients with complex or advanced lung cancer receive coordinated, evidence-based care and access to innovative clinical trials and translational research throughout their treatment journey and follow-up.

More: small-cell lung cancer——systemic therapy; lung cancer screening——early detection; thoracic tumours——diagnosis and staging; drug resistance——research and management; immunotherapy——patient selection

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. ADJUVANT Trial (CTONG1104): Adjuvant Gefitinib for Resected EGFR-Mutant NSCLC
This randomized phase 3 trial led by Dr. Wu Yilong compared adjuvant gefitinib with vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA non-small-cell lung cancer. It showed significantly longer disease-free survival, reduced toxicity and better quality of life, helping establish postoperative targeted therapy as a treatment option for EGFR-mutation-positive lung cancer patients.
2. ADAURA Trial: Adjuvant Osimertinib for Resected EGFR-Mutant Lung Cancer
In this global phase 3 study, Dr. Wu Yilong helped evaluate three years of adjuvant osimertinib in patients with completely resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Adjuvant osimertinib markedly prolonged disease-free and overall survival and reduced brain relapse, becoming a worldwide standard of care for early-stage EGFR-mutant lung cancer after surgery.
3. ARTEMIS-CTONG1509: Bevacizumab Plus Erlotinib for Advanced EGFR-Mutant NSCLC
This multicenter phase 3 trial led by Dr. Wu Yilong tested bevacizumab plus erlotinib versus erlotinib alone in untreated Chinese patients with advanced EGFR-mutated non-small-cell lung cancer. The combination significantly extended progression-free survival, with extra benefit in patients harbouring the L858R mutation or brain metastases, offering an effective first-line treatment option.
4. CTONG1901: Sintilimab Versus Pembrolizumab in Advanced Non-Small-Cell Lung Cancer
This randomized phase 2 trial led by Dr. Wu Yilong directly compared the PD-1 inhibitors sintilimab and pembrolizumab, alone or with platinum chemotherapy, as first-line therapy for advanced non-small-cell lung cancer guided by PD-L1 expression. It supported immunotherapy as an effective and accessible treatment approach for Chinese lung cancer patients without targetable driver mutations.
5. CTONG1804: Neoadjuvant Nivolumab With or Without Chemotherapy for Resectable NSCLC
This multicenter phase 2 study led by Dr. Wu Yilong gave neoadjuvant nivolumab, with or without platinum-doublet chemotherapy, to patients with resectable stage IIA-IIIB non-small-cell lung cancer. It showed high rates of major pathological response and promising event-free survival, supporting perioperative immunotherapy as a powerful treatment strategy before lung cancer surgery.
6. CTONG2201: MRD-Guided Adjuvant Therapy Omission After Lung Cancer Surgery
This prospective multicenter study led by Dr. Wu Yilong monitors circulating tumour DNA molecular residual disease after complete resection of stage IB-IIIA non-small-cell lung cancer. Patients with persistently undetectable MRD are followed without adjuvant therapy, exploring a personalised, treatment-de-escalation strategy that spares low-risk lung cancer patients unnecessary chemotherapy.
  • Affiliated Hospital

Where Dr. Wu Yilong practices

Guangzhou

Guangdong Provincial People’s Hospital

Chinese name: 广东省人民医院
Guangdong Provincial People's Hospital, a Grade-A tertiary general hospital founded in 1946, is a national cardiovascular regional medical center with 14 national key specialties, 2,852 licensed beds and 3.4 million annual outpatient visits, ranking top A++ nationally in hospital performance.
Since 1946
80 years of care
2,852
Licensed beds
3.4 million
Annual outpatient visits
14
Licensed beds
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Wu Yilong?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Wu Yilong.